{"filing":{"accession_number":"0001683168-26-007340","cik":"0001534525","ticker":"XBIO","company_name":"Xenetic Biosciences, Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"xenetic_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826007340/xenetic_8k.htm"},"events":[{"id":34670,"run_id":31913,"accession_number":"0001683168-26-007340","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses a pending share exchange transaction between Xenetic Biosciences and Santersus AG, with a definitive Share Exchange Agreement dated September 14, 2026. The transaction involves Santersus becoming a wholly owned subsidiary of Xenetic, with pre-transaction Santersus shareholders expected to own approximately 85% of the combined company. The transaction is valued at $141 million and is expected to close in Q4 2026, constituting a material acquisition/change of control event.","company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38479,"accession_number":"0001683168-26-007340","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a pending share exchange transaction between Xenetic Biosciences and Santersus AG, with a definitive Share Exchange Agreement dated September 14, 2026. The transaction involves Santersus becoming a wholly owned subsidiary of Xenetic, with pre-transaction Santersus shareholders expected to own approximately 85% of the combined company. The transaction is valued at $141 million and is expected to close in Q4 2026, constituting a material acquisition/change of control event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T21:21:37.981047+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38479,"accession_number":"0001683168-26-007340","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a pending share exchange transaction between Xenetic Biosciences and Santersus AG, with a definitive Share Exchange Agreement dated September 14, 2026. The transaction involves Santersus becoming a wholly owned subsidiary of Xenetic, with pre-transaction Santersus shareholders expected to own approximately 85% of the combined company. The transaction is valued at $141 million and is expected to close in Q4 2026, constituting a material acquisition/change of control event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T21:21:37.981047+00:00","company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","filing_date":"2026-09-23"}]}